Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from June 2022.
Each month, we take a look back at the most popular Oncology Nursing News® stories.
Topics from June 2022 include the evolving role of social media in bridging patients together, nurse perspectives on future directions in CAR T-cell therapy development, and the potential limitations surrounding the CDC’s newly proposed opioid prescribing guidelines. Other top stories include a conversation with Ohio End of Life Options founder and executive director, Lisa Vigil Schattinger, MSN, RN, about her personal experience with medical aid in dying and ongoing research to determine whether music can help reduce chemotherapy-induced nausea.
Approval of off-the-shelf CAR T-cell therapy options may provide greater accessibility and benefit to patients according to experts. In this feature, Oncology Nursing News® speaks with Brittney Baer, BSN, RN, and Kelly Garvin, BSN, RN, OCN, about the evolution of CAR T-cell therapy options and whether off-the-shelf options may become available in the near future.
Although the CDC has put forth a strong effort to improve its opioid guidelines, many providers still feel that more can be done. In this feature story, Jack Kain, PharmD, discusses the recent changes to clinical guidelines and what questions remain surrounding optimal care with opioid therapy.
Lisa Vigil Schattinger, MSN, RN, discusses her experience with medical aid in dying, and what oncology nurses need to understand when supporting patients at the end of their lives.
Might the day come when the oncology nurse delivers acetaminophen alongside 20 mg of Mozart? Hear from Jason Kiernan, PhD, RN, ACNP, a Michigan State University investigator, who is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
The rise of social media platforms has helped foster a community for adolescent and young adult patients with cancer. Hear as our partners with CancerCare outline how social media can positively fill a unique social need for this patient population.
To stay on top of all the latest news and features subscribe to our newsletter. As always, thank you for reading.
Belantamab Mafodotin Combo Yields Improved OS in Relapsed/Refractory Multiple Myeloma
December 12th 2024Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.
Imlunestrant +/- Abemaciclib Improves PFS in ER+/HER2– Advanced Breast Cancer Subgroup
December 11th 2024Imlunestrant, alone or in combination, may provide an all-oral, targeted therapy option following progression for patients with ESR1-mutant, ER-positive, HER2-negative advanced breast cancer.